CLINICAL TRIAL: A PHASE IIIB, RANDOMIZED, TRIAL OF OPEN-LABEL EFAVIRENZ OR ATAZA

临床试验：开放标签 efavirenz 或 ataza 的 IIIB 期随机试验

• 批准号: 8174517
• 负责人: ERIC S DAAR
• 金额: $ 17.56万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-12-01 至 2010-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8174517
• 关键词: Anti-HIV Agents; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Drug Combinations; Funding; Grant; HIV; Institution; Lamivudine; Phase; Research; Research Personnel; Resources; Ritonavir; Safety; Source; Tenofovir; United States Food and Drug Administration; United States National Institutes of Health; abacavir; efavirenz; emtricitabine; open label; randomized trial

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this research is to compare the safety and efficacy and tolerability of different combinations of anti-HIV drugs. All the anti-HIV drugs that are being used in this study are approved by the U.S. Food and Drug Administration (FDA) for treating HIV. The following drug combinations will be used in this study: ¿?¿Efavirenz (EFV) with emtricitabine (FTC) and tenofovir (TDF) ¿?¿EFV with abacavir (ABC) and lamivudine (3TC) ¿?¿Atazanavir (ATV) with ritonavir (RTV) and FTC/TDF ¿?¿ATV with RTV and ABC/3TC

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 本研究的目的是比较不同的抗HIV药物组合的安全性、有效性和耐受性。这项研究中使用的所有抗艾滋病毒药物都得到了美国食品和药物管理局(FDA)的批准，用于治疗艾滋病毒。这项研究将使用以下药物组合： 依法韦仑(EFV)、恩曲他滨(FTC)和替诺福韦(TDF) 含阿巴卡韦(ABC)和拉米夫定(3TC)的EFV 他扎那韦(ATV)联合利托那韦(RTV)和FTC/TDF 带有RTV和ABC/3TC的亚视